Skip to main content

Table 1 Patient demographics and clinical characteristics a

From: A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

Demographics and characteristics   Brodalumab  
Placebo SC IV   
SC IV All 50 mg 140 mg 210 mg 420 mg 700 mg All Total
(N = 6) (N = 4) (N=10) (N = 6) (N = 6) (N = 6) (N = 6) (N = 6) (N = 30) (N = 40)
Females, n (%) 5 (83) 4 (100) 9 (90) 6 (100) 6 (100) 5 (83) 5 (83) 3 (50) 25 (83) 34 (85)
Race, n (%)           
 White 4 (67) 2 (50) 6 (60) 3 (50) 2 (33) 1 (17) 5 (83) 1 (17) 12 (40) 18 (45)
 Black 1 (17) 1 (25) 2 (20) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5)
 Latino 1 (17) 1 (25) 2 (20) 3 (50) 4 (67) 4 (67) 1 (17) 5 (83) 17 (57) 19 (48)
 Asian 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 1 (3) 1 (3)
Age (yr) 52 (10) 56 (12) 53 (10) 46 (12) 57 (9) 46 (10) 56 (7) 50 (6) 51 (10) 51 (10)
Height (cm) 162 (8) 163 (5) 163 (7) 159 (13) 158 (8) 158 (13) 168 (6) 161 (10) 161 (11) 161 (10)
Weight (kg) 75 (10) 101 (28) 85 (22) 80 (17) 77 (12) 64 (11) 81 (12) 79 (14) 76 (14) 79 (17)
BMI (kg/m2) 29 (4) 37 (9) 32 (7) 33 (14) 31 (3) 26 (3) 29 (4) 31 (4) 30 (7) 30 (7)
Tender/painful joint counts 24 (12) 30 (21) 26 (15) 23 (12) 40 (26) 32 (27) 42 (21) 32 (12) 34 (21) 32 (20)
Swollen joint counts 15 (15) 19 (8) 17 (12) 10 (6) 22 (13) 20 (7) 19 (11) 21 (16) 18 (11) 18 (11)
Patient global assessment of disease activity 72 (23) 57 (22) 67 (23) 57 (16) 68 (23) 51 (25) 44 (18) 54 (23) 55 (21) 57 (22)
Physician global assessment of disease activity 7.7 (1.8) 6.0 (1.8) 7.0 (1.9) 6.7 (2.1) 6.3 (2.2) 7.3 (2.0) 6.8 (1.9) 7.0 (0.9) 6.8 (1.8) 6.9 (1.8)
Patient global assessment of pain 72 (23) 63 (18) 68 (20) 60 (18) 71 (17) 49 (28) 49 (14) 60 (24) 58 (21) 60 (21)
HAQ-DI 1.4 (0.9) 1.4 (0.5) 1.4 (0.7) 1.3 (0.7) 1.7 (0.6) 1.7 (1.0) 1.5 (0.7) 1.7 (0.5) 1.6 (0.7) 1.5 (0.7)
CRP (mg/L) 15 (17) 26 (39) 19 (26) 7 (9) 7 (4) 28 (39) 24 (50) 33 (53) 20 (36) 20 (34)
ESR (mm/h) 27 (23) 39 (29) 32 (26) 19 (11) 16 (11) 23 (15) 23 (28) 41 (45) 24 (26) 26 (25)
RF-positive, n (%) 4 (67) 4 (100) 8 (80) 5 (83) 4 (67) 5 (83) 5 (83) 5 (83) 24 (80) 32 (80)
  1. aBMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; IV, intravenous; RF, rheumatoid factor; SC, subcutaneous. All data are means (SD) unless otherwise indicated.